Alpha-MSH-derived tripeptide
Lys-Pro-Val
KPV is a tiny three-amino-acid peptide made from the last three amino acids of alpha-MSH. Researchers became interested in it because it appears to retain some of alpha-MSH's anti-inflammatory activity — and it keeps showing up in studies involving gut inflammation, inflammatory signalling and tissue repair. The part that gets lost online? Most of that research is still in cells and animals. Human clinical evidence is extremely limited.
Additional chemical identifiers are omitted until verified against a primary source.
KPV stands for lysine – proline – valine. That's literally the whole peptide: three amino acids, snipped from the tail end of a larger one called alpha-MSH.
Researchers have seen KPV turn down inflammatory signalling in several experimental systems, which is why it comes up so often around gut inflammation and immune research. The biology is genuinely interesting. The human evidence is where it gets thin.
Why people care
Gut inflammation gets most of the attention — but it's not the only reason KPV keeps showing up in research.
This is the big one.
KPV has been studied in several experimental models of intestinal inflammation. One key study found it can enter intestinal and immune cells through a transporter called PepT1 and reduce inflammatory signalling, with reduced inflammation also seen in mouse colitis models.
So there's a believable biological story here. These were cell and mouse experiments though — not people taking KPV for IBD.
KPV seems to turn down some of the alarm signals.
Researchers have reported effects on inflammatory pathways including NF-κB and MAP kinase signalling, along with reductions in inflammatory cytokine activity in experimental models. Those pathways are how cells coordinate an inflammatory response.
That makes KPV biologically interesting. It does not prove KPV treats inflammatory disease in humans.
There's repair research too — but don't overread it.
KPV has been studied in wound-healing models. In one rabbit study, topical KPV was associated with faster corneal epithelial repair after injury.
That's an interesting tissue-repair signal. It is not evidence that injectable KPV heals injuries throughout the human body.
Human cells have been studied. Humans have not.
A 2025 study looked at KPV in human keratinocyte models exposed to particulate pollution and reported changes involving inflammatory signalling and oxidative stress.
That gives us useful mechanistic information from human cells. A human cell culture is not a human clinical trial.
Research at a glance
In FDA's 2026 review of KPV for pharmacy compounding, the agency said it had not identified clinical studies or human exposure data for KPV via any route of administration. It also said potential safety risks in humans remain unknown.
There's real preclinical research. There is not an established human clinical evidence base.
See the full evidence breakdownReality check
Depends which claim we're talking about. Here's where the internet gets a little… enthusiastic.
People say“KPV reduces inflammation.”
What we actually knowKPV has shown anti-inflammatory activity in laboratory and animal models. That does not establish clinically meaningful anti-inflammatory effects in people.
People say“KPV heals the gut.”
What we actually knowKPV reduced inflammation in several mouse colitis experiments and showed effects in intestinal-cell models. No human clinical trial has established that KPV heals or treats inflammatory bowel disease.
People say“KPV helps tissue heal.”
What we actually knowKPV has been studied in repair models, including rabbit corneal wound healing. That is much narrower than saying KPV broadly heals human tissues.
People say“KPV must be safe because it's only three amino acids.”
What we actually knowSize is not proof of safety. FDA's 2026 review said it had not identified human exposure data and that potential human safety risks remain unknown.
Read this part
Very little.
KPV gets discussed online in injectable, oral, topical and nasal forms as though human use is already well understood. FDA's 2026 scientific review found none of the human data that would support that.
That does not prove KPV is harmful. It means we do not yet have the human data needed to confidently describe its safety or effectiveness.
Regulatory, quickly
In July 2026, FDA's Pharmacy Compounding Advisory Committee reviewed KPV as a candidate for the Section 503A Bulks List, and narrowly voted in favour of recommending KPV-related bulk substances for inclusion.
That recommendation is non-binding, and inclusion on a compounding list would not make KPV an FDA-approved drug.
Why gut research
Think of PepT1 as a doorway for tiny peptides. Researchers found KPV could use it to get inside intestinal and immune cells — and once inside, it was associated with lower activation of several inflammatory pathways.
That's the reason gut research keeps coming back to it: there's a credible route in, not just an effect nobody can explain.
A plausible mechanism is not the same thing as a proven treatment.
Go deeper
Everything above is the short version.
Every paper we used, the experimental models, what researchers found, where the evidence gets interesting, and where the gaps remain.
Explore all KPV researchThe Pep My Life take
KPV is one of those peptides where the biology is genuinely interesting — especially once you start digging into gut inflammation.
Researchers have found believable mechanisms and repeated anti-inflammatory signals in cells and animals. But there is a massive difference between “this did something interesting in cells and mice” and “this is a proven human treatment”.
Right now KPV lives much closer to the first category. That doesn't make it boring. It makes it early.
The practical side
This page is the explanation. Protocols, calculators and preparation guides live separately, published per vial strength.
Practical guides are published per vial strength because concentration depends on both the amount in the vial and the volume added. Guidance written for one strength does not carry over to another.
Keep exploring
Stay current
Occasional emails when we publish something worth your time. No hype, no product pitches.